Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

GR13 Anti-EGFR (Ab-3) Mouse mAb (225)

Anti-EGFR (Ab-3), mouse monoclonal, clone 225 recognizes the ~170 kDa epidermal growth factor receptor protein. It is validated for use in immunoprecipitation.

Anti-EGFR (Ab-3) Mouse mAb (225) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti- Epidermal Growth Factor Receptor

GR13
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Products

Catalogue NumberPackaging Qty/Pack
GR13-100UG Plastic ampoule 100 μg
Description
OverviewRecognizes the ~170 kDa epidermal growth factor receptor protein. For neutralization studies Cat. No. GR13L is recommended.
Catalogue NumberGR13
Brand Family Calbiochem®
SynonymsAnti- Epidermal Growth Factor Receptor
References
ReferencesHunter T. 1984. Nature 311, 414.
Reynolds, F.H., et. al 1981. Nature 292, 259.
Ushiro, H. and Cohen, S. 1980. J. Biol. Chem. 255, 8363.
Product Information
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Negative controlHL-60 cells
Positive controlA-431 cells
Preservative≤0.1% sodium azide
Quality LevelMQ100
Applications
Application ReferencesOriginal Clone Kawamoto, T., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1337. Neutralization Studies Gill, G., et al. 1984. J. Biol. Chem. 259, 7755. Kawamoto, T., et al. 1984. J. Biol. Chem. 259, 7761. Masui, H., et al. 1984. Cancer Res. 44, 1002. Kawamoto, T., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1337. Sato, J.D., et al. 1983. Biol. Med. 1, 511.
Key Applications Immunoprecipitation
Application NotesImmunoprecipitation (1-2 µg per sample)
Neutralization Studies (2 µg/ml, see application references; use Cat. No. GR13L)
Application CommentsShown to inhibit human tumor xenographs in nude mice. It inhibits EGF binding to its receptor and is an antagonist of in vivo EGF-stimulated tyrosine kinase activity. It also inhibits A431 tumor formation in nude mice. For neutralization studies GR13L is recommended. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenpartially purified, human EGFR from A431 cells
ImmunogenHuman
Clone225
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Yes
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
GR13-100UG 04055977228243

Documentation

Anti-EGFR (Ab-3) Mouse mAb (225) Certificates of Analysis

TitleLot Number
GR13

References

Reference overview
Hunter T. 1984. Nature 311, 414.
Reynolds, F.H., et. al 1981. Nature 292, 259.
Ushiro, H. and Cohen, S. 1980. J. Biol. Chem. 255, 8363.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision25-October-2007 JSW
SynonymsAnti- Epidermal Growth Factor Receptor
ApplicationImmunoprecipitation (1-2 µg per sample)
Neutralization Studies (2 µg/ml, see application references; use Cat. No. GR13L)
DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with NS-1 mouse myeloma cells (see application references). Recognizes the ~170 kDa epidermal growth factor receptor protein.
BackgroundEpidermal growth factor (EGF) initiates its effects on cell growth through interaction with a 170,000 dalton cell surface glycoprotein receptor. Binding of EGF or transforming growth factor a to the receptor activates a tyrosine-specific protein kinase intrinsic to the EGF receptor protein. The phosphotyrosine content of target cells increases rapidly and the EGF receptor is phosphorylated on tyrosine residues. Subsequent to binding, EGF receptor complexes are internalized and cell proliferation takes place with partially-purified EGF receptor from human A431 epidermal carcinoma cells.
HostMouse
Immunogen speciesHuman
Immunogenpartially purified, human EGFR from A431 cells
Clone225
IsotypeIgG₁
Specieshuman, not mouse, not rat
Positive controlA-431 cells
Negative controlHL-60 cells
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsShown to inhibit human tumor xenographs in nude mice. It inhibits EGF binding to its receptor and is an antagonist of in vivo EGF-stimulated tyrosine kinase activity. It also inhibits A431 tumor formation in nude mice. For neutralization studies GR13L is recommended. Antibody should be titrated for optimal results in individual systems.
Storage +2°C to +8°C
Do Not Freeze Yes
Toxicity Standard Handling
ReferencesHunter T. 1984. Nature 311, 414.
Reynolds, F.H., et. al 1981. Nature 292, 259.
Ushiro, H. and Cohen, S. 1980. J. Biol. Chem. 255, 8363.
Application referencesOriginal Clone Kawamoto, T., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1337. Neutralization Studies Gill, G., et al. 1984. J. Biol. Chem. 259, 7755. Kawamoto, T., et al. 1984. J. Biol. Chem. 259, 7761. Masui, H., et al. 1984. Cancer Res. 44, 1002. Kawamoto, T., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1337. Sato, J.D., et al. 1983. Biol. Med. 1, 511.